Advancing Quantification of Diffusion MRI for Oncologic Imaging

推进肿瘤成像扩散 MRI 的量化

• 批准号: 9759773
• 负责人: THOMAS L CHENEVERT
• 金额: $ 49.2万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-05-09 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9759773
• 关键词: Address; Adopted; Advanced Development; Algorithms; American College of Radiology Imaging Network; Architecture; Award; Biological Models; Breast; Breast Cancer Patient; Cancer Center; Cancer Patient; Characteristics; Clinical; Clinical Data; Clinical Management; Clinical Trials; Clinical Trials Database; Collaborations; Data; Detection; Development; Diagnostic; Diagnostic radiologic examination; Diffusion; Diffusion Magnetic Resonance Imaging; Environment; Evaluation; Goals; Human; Ice; Image; Image Analysis; Imaging technology; In Situ; Industrialization; Institutes; Investigation; Magnetic Resonance Imaging; Malignant Neoplasms; Measurement; Measures; Medical Imaging; Methods; Modification; Molecular Analysis; Monitor; Multi-Institutional Clinical Trial; Multicenter Trials; Non-Invasive Cancer Detection; Outcome; Pathologic; Patients; Performance; Prediction of Response to Therapy; Protocol Compliance; Protocols documentation; Reproducibility; Research; Research Design; Scanning; Site; Source; Standardization; System; Systematic Bias; Systems Development; Techniques; Technology; Temperature; Testing; Thermometry; Tissues; Tube; Validation; Water; Weight; base; cancer imaging; clinical research site; clinically relevant; comparative; computerized; design; diffusion weighted; imaging platform; improved; improved outcome; malignant breast neoplasm; multi-site trial; next generation; personalized management; prognostic; prototype; public health relevance; quality assurance; quantitative imaging; response; success; technology development; tool; treatment response; tumor; water diffusion

 DESCRIPTION (provided by applicant): This renewal continues efforts toward establishing diffusion-weighted MRI (DWI) as a quantitative imaging metric for cancer patients. Based upon our progress to date, this renewal effort will be advanced through three Specific Aims along with strategic collaborations within the NCI Quantitative Imaging Network (QIN), Imbio, LLC (industrial partner) and the National Institute of Standards and Technology (NIST). (Aim 1) Development of a standardized platform for diffusion analysis and validation of DWI metrics for quantification of tumor diffusion values will be accomplished through establishment of histogram and voxel-based metrics. (Aim 2) In collaboration with NIST, development of the next generation DWI phantom using in-situ thermometry for precise diffusion measurements over the full clinically-relevant ADC range to generate quantitative quality assurance and system performance metrics across diverse scanner platforms. (Aim 3) Based on measured system characteristics, implementation of retrospective correction of DW nonlinearity errors in multi-center trials is possible. This research effort will address major hurdles in establishing DWI for therapeutic response assessment to improve clinical management of cancer patients. We will develop and rigorously test a medical imaging platform allowing for a standardized implementation and clinical validation of advanced DWI analytical techniques for quantification of tumor diffusion values across multiple MRI systems. We will also continue the success of our widely-adopted ice water DWI phantom with the development of a next-generation DWI phantom platform that will provide quantitative diffusion measurements over the full tissue range of diffusion values. Finally, we will provide a strategy for resolving a major source of technical variability in DWI related to instrumental bias from differences in MRI gradient systems through the development of system-specific correction tools. The renewal of our QIN project will provide advanced analytical and quality assurance support to clinical trials including I-SPY2 (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis, ACRIN 6698, and ACRIN 6702. Success of this endeavor will significantly advance the clinical management of cancer patients ultimately improving outcomes.

 描述（由申请人提供）：本次更新继续努力将弥散加权MRI（DWI）确立为癌症患者的定量成像指标。根据我们迄今为止的进展，这项更新工作将通过三个特定目标沿着与NCI定量成像网络（QIN）、Imbio，LLC（工业合作伙伴）和美国国家标准与技术研究院（NIST）的战略合作来推进。(Aim 1）通过建立直方图和基于体素的指标，完成扩散分析标准化平台的开发和量化肿瘤扩散值的DWI指标的验证。(Aim 2）与NIST合作，开发下一代DWI体模，使用原位测温法在整个临床相关ADC范围内进行精确扩散测量，以在不同扫描仪平台上生成定量质量保证和系统性能指标。(Aim 3）基于测量的系统特性，可以在多中心试验中实施DW非线性误差的回顾性校正。这项研究工作将解决建立DWI治疗反应评估的主要障碍，以改善癌症患者的临床管理。我们将开发并严格测试一个医学成像平台，允许标准化实施和临床验证先进的DWI分析技术，用于在多个MRI系统中量化肿瘤扩散值。我们还将继续我们广泛采用的冰水DWI体模的成功，开发下一代DWI体模平台，该平台将提供全组织范围内扩散值的定量扩散测量。最后，我们将提供一种策略，通过开发系统特定的校正工具，解决DWI中与MRI梯度系统差异相关的仪器偏倚的主要技术变异性来源。我们QIN项目的更新将为临床试验提供先进的分析和质量保证支持，包括I-SPY 2（通过成像和分子分析预测治疗反应的系列研究调查）、ACRIN 6698和ACRIN 6702。这一奋进的成功将大大推进癌症患者的临床管理，最终改善预后。

项目成果

Apparent diffusion coefficient is highly reproducible on preclinical imaging systems: Evidence from a seven-center multivendor study.

• DOI: 10.1002/jmri.24955
• 发表时间: 2015-12
• 期刊: Journal of magnetic resonance imaging : JMRI
• 作者: Doblas S;Almeida GS;Blé FX;Garteiser P;Hoff BA;McIntyre DJ;Wachsmuth L;Chenevert TL;Faber C;Griffiths JR;Jacobs AH;Morris DM;O'Connor JP;Robinson SP;Van Beers BE;Waterton JC
• 通讯作者: Waterton JC